211 related articles for article (PubMed ID: 29915268)
1. Low circulating chemerin levels correlate with hepatic dysfunction and increased mortality in decompensated liver cirrhosis.
Horn P; von Loeffelholz C; Forkert F; Stengel S; Reuken P; Aschenbach R; Stallmach A; Bruns T
Sci Rep; 2018 Jun; 8(1):9242. PubMed ID: 29915268
[TBL] [Abstract][Full Text] [Related]
2. Reduced serum chemerin in patients with more severe liver cirrhosis.
Eisinger K; Krautbauer S; Wiest R; Weiss TS; Buechler C
Exp Mol Pathol; 2015 Apr; 98(2):208-13. PubMed ID: 25595667
[TBL] [Abstract][Full Text] [Related]
3. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality.
Zimmermann HW; Reuken PA; Koch A; Bartneck M; Adams DH; Trautwein C; Stallmach A; Tacke F; Bruns T
J Intern Med; 2013 Jul; 274(1):86-100. PubMed ID: 23432143
[TBL] [Abstract][Full Text] [Related]
4. Circulating lipocalin 2 is neither related to liver steatosis in patients with non-alcoholic fatty liver disease nor to residual liver function in cirrhosis.
Meier EM; Pohl R; Rein-Fischboeck L; Schacherer D; Eisinger K; Wiest R; Krautbauer S; Buechler C
Cytokine; 2016 Sep; 85():45-50. PubMed ID: 27288631
[TBL] [Abstract][Full Text] [Related]
5. Prognostic markers in patients with ascites and hepatorenal syndrome.
Nazal L; Cárdenas A
Dis Markers; 2011; 31(3):139-46. PubMed ID: 22045399
[No Abstract] [Full Text] [Related]
6. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery.
Sell H; Divoux A; Poitou C; Basdevant A; Bouillot JL; Bedossa P; Tordjman J; Eckel J; Clément K
J Clin Endocrinol Metab; 2010 Jun; 95(6):2892-6. PubMed ID: 20375212
[TBL] [Abstract][Full Text] [Related]
7. Impact of serum chemerin levels on liver functional reserves and platelet counts in patients with hepatocellular carcinoma.
Imai K; Takai K; Hanai T; Shiraki M; Suzuki Y; Hayashi H; Naiki T; Nishigaki Y; Tomita E; Shimizu M; Moriwaki H
Int J Mol Sci; 2014 Jun; 15(7):11294-306. PubMed ID: 24968270
[TBL] [Abstract][Full Text] [Related]
8. Immune dysfunction in cirrhosis: Distinct cytokines phenotypes according to cirrhosis severity.
Dirchwolf M; Podhorzer A; Marino M; Shulman C; Cartier M; Zunino M; Paz S; Muñoz A; Bocassi A; Gimenez J; Di Pietro L; Romero G; Fainboim H; Fainboim L
Cytokine; 2016 Jan; 77():14-25. PubMed ID: 26517154
[TBL] [Abstract][Full Text] [Related]
9. Clinical Implications of the Serum Apelin Level on Portal Hypertension and Prognosis of Liver Cirrhosis.
Lim YL; Choi E; Jang YO; Cho YZ; Kang YS; Baik SK; Kwon SO; Kim MY
Gut Liver; 2016 Jan; 10(1):109-16. PubMed ID: 25963087
[TBL] [Abstract][Full Text] [Related]
10. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes.
Weigert J; Neumeier M; Wanninger J; Filarsky M; Bauer S; Wiest R; Farkas S; Scherer MN; Schäffler A; Aslanidis C; Schölmerich J; Buechler C
Clin Endocrinol (Oxf); 2010 Mar; 72(3):342-8. PubMed ID: 19558533
[TBL] [Abstract][Full Text] [Related]
11. Chemerin, retinol binding protein-4, cytokeratin-18 and transgelin-2 presence in sera of patients with non-alcoholic liver fatty disease.
Zwolak A; Szuster-Ciesielska A; Daniluk J; Semeniuk J; Kandefer-Szerszen M
Ann Hepatol; 2016 Nov-Dec 2016; 15(6):862-869. PubMed ID: 27740519
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing serum chemerin and kallistatin concentrations in patients with alcohol-induced liver cirrhosis.
Prystupa A; Kiciński P; Luchowska-Kocot D; Sak J; Prystupa TK; Tan YH; Panasiuk L; Załuska W
Ann Agric Environ Med; 2019 Mar; 26(1):143-147. PubMed ID: 30922045
[TBL] [Abstract][Full Text] [Related]
13. High ascitic fluid leptin levels in patients with decompensated liver cirrhosis and sterile ascites: relationship with TNF-alpha levels.
Giannini E; Romagnoli P; Tenconi GL; Botta F; Malfatti F; Chiarbonello B; Mamone M; Barreca T; Testa R
Dig Dis Sci; 2004 Feb; 49(2):275-80. PubMed ID: 15104370
[TBL] [Abstract][Full Text] [Related]
14. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
[TBL] [Abstract][Full Text] [Related]
15. Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis.
Juanola O; Ferrusquía-Acosta J; García-Villalba R; Zapater P; Magaz M; Marín A; Olivas P; Baiges A; Bellot P; Turon F; Hernández-Gea V; González-Navajas JM; Tomás-Barberán FA; García-Pagán JC; Francés R
FASEB J; 2019 Oct; 33(10):11595-11605. PubMed ID: 31345057
[TBL] [Abstract][Full Text] [Related]
16. Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis.
Trebicka J; Amoros A; Pitarch C; Titos E; Alcaraz-Quiles J; Schierwagen R; Deulofeu C; Fernandez-Gomez J; Piano S; Caraceni P; Oettl K; Sola E; Laleman W; McNaughtan J; Mookerjee RP; Coenraad MJ; Welzel T; Steib C; Garcia R; Gustot T; Rodriguez Gandia MA; Bañares R; Albillos A; Zeuzem S; Vargas V; Saliba F; Nevens F; Alessandria C; de Gottardi A; Zoller H; Ginès P; Sauerbruch T; Gerbes A; Stauber RE; Bernardi M; Angeli P; Pavesi M; Moreau R; Clària J; Jalan R; Arroyo V
Front Immunol; 2019; 10():476. PubMed ID: 30941129
[No Abstract] [Full Text] [Related]
17. Assessing the risk of decompensation by ascites and spontaneous bacterial peritonitis in cirrhosis.
Dănulescu RM; Stanciu C; Trifan A
Rev Med Chir Soc Med Nat Iasi; 2014; 118(2):320-6. PubMed ID: 25076694
[TBL] [Abstract][Full Text] [Related]
18. Zonulin Family Peptide Levels in Ascites and Serum in Patients with Liver Cirrhosis: A Preliminary Study.
Pietrukaniec M; Migacz M; Żak-Gołąb A; Olszanecka-Glinianowicz M; Chudek J; Duława J; Holecki M
Dis Markers; 2019; 2019():2804091. PubMed ID: 31781297
[TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites.
Thaler J; Lisman T; Quehenberger P; Hell L; Schwabl P; Scheiner B; Bucsics T; Nieuwland R; Ay C; Trauner M; Pabinger I; Reiberger T; Mandorfer M
Thromb Haemost; 2022 Mar; 122(3):353-362. PubMed ID: 34020489
[TBL] [Abstract][Full Text] [Related]
20. Chemerin as a novel non-invasive serum marker of intrahepatic lipid content in obese children.
Kłusek-Oksiuta M; Bialokoz-Kalinowska I; Tarasów E; Wojtkowska M; Werpachowska I; Lebensztejn DM
Ital J Pediatr; 2014 Nov; 40():84. PubMed ID: 25399407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
